– UK, Watford – Smith & Nephew Plc (LON: SN / NYSE: SNN), the global medical technology company, announced the appointment of Dr. Garheng Kong to its Board as an Independent Non-Executive Director effective from 1 September 2025.
Dr. Garheng Kong will also join the Audit Committee.
About Dr. Garheng Kong
Dr. Garheng Kong is managing partner and co-founder of HealthQuest Capital. He also serves as lead independent director of Laboratory Corporation of America (LabCorp) and a non-executive director of Xeris Biopharma Holdings Inc., LunitInc.c and IKS Health. Garheng was previously managing general partner of Sofinnova Investments, Inc., and served as a non-executive director of Venus Concept, Inc., Alimera Sciences, and Avedro, Inc., and as chair of Histogenics Corporation.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration, and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & EN, T, and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LON: SN, NYSE: SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more: https://www.smith-nephew.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.